Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx, Inc. President and CEO Michael Raab reported new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he received 446,220 RSUs at a price of $0, each RSU convertible into one share of common stock upon vesting. On the same date, he was granted a stock option for 669,330 shares of common stock at an exercise price of $7.77 per share, which vests in 48 equal monthly installments starting January 23, 2026, subject to continued service. Following these grants, Raab directly holds 1,902,968 shares of Ardelyx common stock, with additional indirect holdings of 24,364 shares and 1,000 shares through family trusts.
Ardelyx, Inc. reported an equity compensation grant to its Chief Human Resources Officer effective January 23, 2026. The officer received 99,455 restricted stock units (RSUs), with each RSU settling into one share of common stock upon vesting, increasing the officer’s directly held common stock to 265,455 shares. On the same date, the officer was also granted a stock option for 149,185 shares of common stock at an exercise price of $7.77 per share. The option vests in 48 equal monthly installments starting from January 23, 2026, conditioned on continued employment or service, and will remain exercisable until January 23, 2036.
Ardelyx Chief Patient Officer receives new equity awards. Laura A. Williams reported a grant of 82,695 shares of Ardelyx common stock on January 23, 2026, issued at $0 per share as restricted stock units that convert 1-for-1 into common stock when they vest. She also received a stock option for 124,040 shares of common stock at an exercise price of $7.77 per share, granted at no cost. The option vests in 48 equal monthly installments starting January 23, 2026, conditioned on her continued employment or service. Following these transactions, Williams directly beneficially owned 444,258 shares of Ardelyx common stock.
Ardelyx, Inc. reported an equity award to executive John E. Bishop, its Chief Technical and Quality Officer. On January 23, 2026, he received 124,330 shares of Common Stock in the form of restricted stock units, at a price of $0 per share, bringing his directly held Common Stock to 342,330 shares after the grant. He was also granted a stock option for 186,500 shares of Common Stock with an exercise price of $7.77 per share. The option vests in 48 equal monthly installments beginning on January 23, 2026, subject to his continued employment or service, and is exercisable through January 23, 2036.
Ardelyx, Inc. received a Schedule 13G filing from hedge fund–related entities reporting significant passive ownership of its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 12,855,317 shares, representing 5.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 13,121,781 shares, or 5.4% of the class, with shared voting and dispositive power and no sole authority. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Ardelyx, but instead are held on a passive basis.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an option exercise and share sale in Ardelyx common stock. On January 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $0.99 per share, then sold 50,000 shares at a weighted average price of $6.978 per share, with individual trades executed between $6.97 and $7.00.
After these transactions, Williams directly owned 361,563 shares of Ardelyx common stock, a figure that reflects an earlier purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. She also held 62,000 stock options with a $0.99 exercise price, expiring on January 6, 2032, which vest in equal monthly installments that began in January 2022.
Ardelyx stockholder plans to sell shares under Rule 144. A notice was filed for the planned sale of 50,000 shares of Ardelyx common stock through Morgan Stanley Smith Barney LLC on or around 01/08/2026, listed with an aggregate market value of $291,500. The shares are to be sold on the NASDAQ, and the filing shows total Ardelyx shares outstanding of 242,974,306.
The 50,000 shares were acquired the same day, 01/08/2026, via a cash exercise of stock options granted by the issuer. The filing also reports that Laura A. Williams sold 6,426 Ardelyx common shares in a prior transaction on 11/21/2025 for gross proceeds of $35,580.12. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the company.
Ardelyx, Inc. reported preliminary, unaudited product sales for 2025. U.S. net product sales revenue of IBSRELA® (tenapanor) was approximately $87 million in the fourth quarter and approximately $274 million for the full year ended December 31, 2025. U.S. net product sales revenue of XPHOZAH® (tenapanor) was approximately $28 million in the fourth quarter and approximately $104 million for the full year.
The company also indicated it had approximately $265 million in cash, cash equivalents, and short-term investments as of December 31, 2025, on an unaudited basis. All figures are preliminary, may be adjusted during the audit process, and have not been audited or reviewed by Ernst & Young LLP.
Ardelyx, Inc. reported senior leadership changes effective December 31, 2025. Elizabeth Grammer resigned as Chief Legal and Administrative Officer, but will continue as General Counsel until a successor is named and then serve as a Senior Advisor for 24 months under a Transition and Separation Agreement. During an initial 12‑month employment period, she will keep her current base salary, remain eligible for an annual target bonus equal to 45% of base salary for 2025, and continue to receive senior non‑executive benefits, followed by a one‑month salary payment if she delivers a general release.
In the second 12 months, her equity will continue to vest, she may receive advisory payments for the first nine months, and Ardelyx will pay COBRA health premiums for her and dependents during the advisory term or until she gains other coverage. Separately, Chief Medical Officer Edward Conner, M.D. will resign for personal reasons, and Chief Patient Officer and former CMO Dr. Laura Williams will act as interim Chief Medical Officer, overseeing clinical development until a permanent replacement is hired.
Ardelyx, Inc. (ARDX) insider activity: Chief Legal and Administrative Officer Elizabeth Grammer reported a Form 4 transaction dated 11/21/2025. She sold 5,995 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, and the shares were sold solely to cover applicable withholding taxes.
After this transaction, she beneficially owns 299,895 shares of Ardelyx common stock directly.